Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 6, 2014, Pages 1297-1305

  Li, Heyan ^a   Takayama, Koichi ^a   Wang, Shuo ^a   Shiraishi, Yoshimasa ^a   Gotanda, Keisuke ^b   Harada, Taishi ^a   Furuyama, Kazuto ^a   Iwama, Eiji ^a   Ieiri, Ichiro ^b   Okamoto, Isamu ^a   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Drug concentration; Erlotinib; Non small cell lung cancer; VEGF protein

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

A549 CELL LINE; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH ASSAY; CONTROLLED STUDY; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MTS ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922003017     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2610-x     Document Type: Article

References (42)

1. Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77(3):311-319
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA-Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA-Cancer J Clin 63(1):11-30. doi: 10.3322/caac.21166
4. Custodio A, Mendez M, Provencio M (2012) Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001
5. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva (R)) tablets. Oncologist 10(7):461-466. doi: 10.1634/theoncologist.10-7-461
6. Stenger M (2013) Erlotinib in first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or exon 21 (L858R) substitution the ASCO post 4(11):68
7. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713-718. doi: 10.1634/theoncologist.12-6-713
8. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C (2009) Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 15(10):3495-3502. doi: 10.1158/1078-0432.ccr-08-2407
9. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5(3):203-220. doi: 10.1158/1541-7786.mcr-06-0404
10. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-2555. doi: 10.1200/jco.2005.02.477
11. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 25(30):4743-4750. doi: 10.1200/jco.2007.12.3026
12. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V (2013) ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 31(31):3926-3934. doi: 10.1200/jco.2012.47.3983
13. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377(9780):1846-1854
14. Viloria-Petit AM, Kerbel RS (2004) Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 58(3):914-926. doi: 10.1016/j.ijrobp.2003.09.091
15. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427. doi: 10.1038/nrd3455
16. Heskamp S, Boerman OC, Molkenboer-Kuenen JDM, Oyen WJG, van der Graaf WTA, van Laarhoven HWM (2013) Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 133(2):307-314. doi: 10.1002/ijc.28046
17. Van der Veldt AAM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter H, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF (2012) Rapid decrease in delivery of chemotherapy to tumors after Anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21(1):82-91. doi: 10.1016/j.ccr.2011.11.023
18. Takayama K, Reynolds PN, Adachi Y, Kaliberova L, Uchino J, Nakanishi Y, Curiel DT (2007) Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. Cancer Gene Ther 14(1):105-116. doi: 10.1038/sj.cgt.7700991
19. Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K (2012) Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer 12:3-11. doi: 10.1186/1471-2407-12-37
20. Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, Wallace J, Straughan DW (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58(1):109-113
21. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Janne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-3494. doi: 10.1158/1078-0432.ccr-08-2904
22. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y (2006) Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 57(5):693-702. doi: 10.1007/s00280-005-0079-3
23. Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth factors (Chur, Switzerland) 7(1):53-64. doi: 10.3109/08977199209023937
24. Presta LG, Chen H, OConnor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599
25. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G (2008) Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 99(1):93-99. doi: 10.1038/sj.bjc.6604429
26. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ, Ellis LM (2001) Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85(4):584-589. doi: 10.1054/bjoc.2001.1936
27. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291(2):739-748
28. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jurgensmeier JM, Womack C (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16(14):3548-3561. doi: 10.1158/1078-0432.ccr-09-2797
29. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591. doi: 10.1038/nrc2403
30. Welti J, Loges S, Dimmeler S, Carmeliet P (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123(8):3190-3200. doi: 10.1172/jci70212
31. Yewale C, Baradia D, Vhora I, Patil S, Misra A (2013) Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34(34):8690-8707. doi: 10.1016/j.biomaterials.2013.07.100
32. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57(21):4838-4848
33. Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL (2008) Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 265(2):307-317. doi: 10.1016/j.canlet.2008.02.064
34. Ebos JML, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8(4):210-221. doi: 10.1038/nrclinonc.2011.21
35. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K (2009) S0536: carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 27(15):2
36. Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S, Pages G (2010) Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer 46(16):3022-3036. doi: 10.1016/j.ejca.2010.07.021
37. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, Bauer TT, Mairinger T (2013) The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 3(4):e002560. doi: 10.1136/bmjopen-2013-002560
38. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, Guallar E, Lee G, Lee J, Shim YM (2013) EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS ONE 8(2):7. doi: 10.1371/journal.pone.0056011
39. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M, Spanish Lung Canc G (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16(7):1081-1086. doi: 10.1093/annonc/mdi221
40. Usui K, Ushijima T, Tanaka Y, Tanai C, Noda H, Abe N, Horiuchi H, Ishihara T (2011) The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulm Med 2011:290132. doi: 10.1155/2011/290132
41. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817-1824. doi: 10.1111/j.1349-7006.2007.00607.x
42. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JCM, Chu DT, Zaatar A, Sanchez JAO, Vu VV, Au JSK, Inoue A, Lee SM, Gebski V, Yang JCH (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. JNCI Natl Cancer Inst 105(9):595-605. doi: 10.1093/jnci/djt072